NCT06054035 - SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

September 30, 2027

Conditions

Type2diabetesPreDiabetesRenal Failure

Interventions

DRUG

Dapagliflozin (Forxiga®)

Dapagliflozin 10 mg once daily for 6 months. Route of administration: oral.

DRUG

Placebo matching Dapaglifolzin

Placebo matching Dapaglifolzin once daily for 6 months. Route of administration: oral.

BEHAVIORAL

Lifestyle Intervention

Patients receive a conventional lifestyle intervention (one in depth individual session at the beginning and standard care information on a healthy lifestyle at every visit thereafter).

Trial Locations (9)

23562

NOT_YET_RECRUITING

Medizinische Klinik I, UKSH Campus LübeckAG Meyhöfer - Endocrinology, Diabetes & Metabolism, Lübeck

40225

RECRUITING

German Diabetes Center, Leibniz-Center for Diabetes Research at the Heinrich-Heine-University Duesseldorf, Düsseldorf

69120

RECRUITING

Heidelberg University Hospital - Department of Endocrinology and Metabolism, Heidelberg

72076

RECRUITING

University Hospital Tuebingen, Otfried-Mueller Str. 10, Tübingen

Unknown

RECRUITING

Charité Universitätsmedizin Berlin, Klinik für Endokrinologie und Stoffwechselmedizin, Berlin

RECRUITING

Universitätsstudienzentrum für Stoffwechselerkrankungen , Medizinische Klinik und Poliklinik III, Dresden

RECRUITING

Medizinische Klinik und Poliklinik III - Bereich Endokrinologie, Leipzig

RECRUITING

Diabetes Center Med. Klinik und Poliklinik IV, Klinikum der Universität München, LMU, München

NOT_YET_RECRUITING

Institut für Ernährungsmedizin, Technische Universität München, München